Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 27 | 2026 | 1147 | 3.340 |
Why?
|
| Tissue and Organ Procurement | 8 | 2022 | 254 | 2.670 |
Why?
|
| Tissue Donors | 14 | 2022 | 506 | 2.140 |
Why?
|
| Organ Transplantation | 5 | 2025 | 175 | 1.830 |
Why?
|
| Kidney Transplantation | 7 | 2022 | 558 | 1.320 |
Why?
|
| Graft Rejection | 7 | 2026 | 552 | 1.310 |
Why?
|
| Donor Selection | 3 | 2020 | 60 | 1.300 |
Why?
|
| Thrombosis | 3 | 2022 | 499 | 1.110 |
Why?
|
| Biliary Atresia | 3 | 2025 | 223 | 0.960 |
Why?
|
| Transplant Recipients | 6 | 2025 | 235 | 0.920 |
Why?
|
| Kidney Failure, Chronic | 4 | 2021 | 934 | 0.780 |
Why?
|
| Venous Thrombosis | 2 | 2022 | 164 | 0.770 |
Why?
|
| Death | 2 | 2021 | 78 | 0.760 |
Why?
|
| Cholestasis | 1 | 2025 | 170 | 0.750 |
Why?
|
| Immunosuppressive Agents | 3 | 2026 | 663 | 0.690 |
Why?
|
| Waiting Lists | 6 | 2024 | 253 | 0.620 |
Why?
|
| Health Care Rationing | 1 | 2020 | 58 | 0.610 |
Why?
|
| Graft Survival | 10 | 2022 | 465 | 0.610 |
Why?
|
| Immunocompromised Host | 2 | 2026 | 315 | 0.610 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 93 | 0.560 |
Why?
|
| Perioperative Care | 1 | 2020 | 217 | 0.550 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2019 | 133 | 0.540 |
Why?
|
| Liver Diseases | 1 | 2022 | 385 | 0.540 |
Why?
|
| Betacoronavirus | 1 | 2020 | 275 | 0.500 |
Why?
|
| End Stage Liver Disease | 5 | 2024 | 193 | 0.490 |
Why?
|
| Patient Selection | 1 | 2020 | 729 | 0.480 |
Why?
|
| Pandemics | 2 | 2020 | 1118 | 0.480 |
Why?
|
| Portal Vein | 3 | 2022 | 84 | 0.480 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 339 | 0.450 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 351 | 0.450 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 712 | 0.410 |
Why?
|
| Adenovirus Infections, Human | 2 | 2026 | 60 | 0.410 |
Why?
|
| Child | 25 | 2026 | 26341 | 0.360 |
Why?
|
| Humans | 44 | 2026 | 131163 | 0.350 |
Why?
|
| Registries | 1 | 2019 | 1634 | 0.350 |
Why?
|
| Length of Stay | 5 | 2021 | 1421 | 0.340 |
Why?
|
| Infant | 16 | 2026 | 13352 | 0.330 |
Why?
|
| Retrospective Studies | 25 | 2026 | 17753 | 0.320 |
Why?
|
| Child, Preschool | 17 | 2026 | 15110 | 0.300 |
Why?
|
| Adolescent | 17 | 2025 | 20987 | 0.290 |
Why?
|
| Iliac Vein | 2 | 2019 | 24 | 0.290 |
Why?
|
| Allografts | 5 | 2021 | 220 | 0.280 |
Why?
|
| Vascular Grafting | 2 | 2019 | 51 | 0.280 |
Why?
|
| Male | 24 | 2026 | 64957 | 0.250 |
Why?
|
| Treatment Outcome | 12 | 2024 | 12936 | 0.240 |
Why?
|
| Risk Factors | 16 | 2025 | 11074 | 0.240 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2026 | 55 | 0.240 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 293 | 0.230 |
Why?
|
| Infant, Newborn | 7 | 2025 | 8635 | 0.230 |
Why?
|
| Adenoviridae Infections | 1 | 2026 | 75 | 0.230 |
Why?
|
| Antibodies | 1 | 2026 | 322 | 0.220 |
Why?
|
| Hypernatremia | 1 | 2024 | 32 | 0.210 |
Why?
|
| Female | 24 | 2026 | 70963 | 0.200 |
Why?
|
| Sirolimus | 1 | 2025 | 230 | 0.200 |
Why?
|
| Autoantibodies | 1 | 2026 | 451 | 0.190 |
Why?
|
| Hepatic Artery | 1 | 2022 | 45 | 0.180 |
Why?
|
| Catheters | 1 | 2022 | 78 | 0.180 |
Why?
|
| Postoperative Period | 2 | 2020 | 331 | 0.170 |
Why?
|
| Liver Failure, Acute | 1 | 2023 | 98 | 0.170 |
Why?
|
| Hepatoblastoma | 1 | 2023 | 204 | 0.170 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 3061 | 0.160 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 104 | 0.160 |
Why?
|
| Thrombectomy | 1 | 2021 | 117 | 0.160 |
Why?
|
| Gastroenteritis | 1 | 2023 | 308 | 0.160 |
Why?
|
| Age Factors | 5 | 2021 | 2825 | 0.160 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 501 | 0.160 |
Why?
|
| Hospitalization | 2 | 2020 | 1950 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2024 | 1071 | 0.160 |
Why?
|
| Postoperative Complications | 2 | 2026 | 3147 | 0.160 |
Why?
|
| Twins, Conjoined | 1 | 2020 | 29 | 0.150 |
Why?
|
| Attitude | 1 | 2020 | 111 | 0.150 |
Why?
|
| Public Opinion | 1 | 2020 | 64 | 0.150 |
Why?
|
| Learning Curve | 1 | 2020 | 54 | 0.150 |
Why?
|
| Renal Veins | 1 | 2019 | 31 | 0.150 |
Why?
|
| Models, Anatomic | 1 | 2020 | 105 | 0.150 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 88 | 0.150 |
Why?
|
| Directed Tissue Donation | 1 | 2019 | 3 | 0.150 |
Why?
|
| Clinical Protocols | 1 | 2020 | 230 | 0.150 |
Why?
|
| Tetrazoles | 1 | 2019 | 70 | 0.140 |
Why?
|
| Anastomosis, Surgical | 1 | 2019 | 176 | 0.140 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2018 | 38 | 0.140 |
Why?
|
| Cold Ischemia | 1 | 2018 | 29 | 0.130 |
Why?
|
| Cardiomyopathies | 1 | 2023 | 514 | 0.130 |
Why?
|
| Blood Loss, Surgical | 1 | 2019 | 168 | 0.130 |
Why?
|
| Imidazoles | 1 | 2019 | 219 | 0.130 |
Why?
|
| Erythrocyte Transfusion | 1 | 2019 | 146 | 0.130 |
Why?
|
| Anticoagulants | 1 | 2022 | 605 | 0.130 |
Why?
|
| Liver Failure | 1 | 2017 | 99 | 0.120 |
Why?
|
| Kidney | 2 | 2022 | 1282 | 0.120 |
Why?
|
| Blood Group Incompatibility | 1 | 2016 | 28 | 0.120 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2016 | 89 | 0.120 |
Why?
|
| Aorta | 1 | 2019 | 521 | 0.120 |
Why?
|
| ABO Blood-Group System | 1 | 2016 | 61 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2021 | 722 | 0.110 |
Why?
|
| Heart Transplantation | 1 | 2022 | 800 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2017 | 483 | 0.110 |
Why?
|
| Reoperation | 1 | 2018 | 818 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 982 | 0.110 |
Why?
|
| Critical Care | 2 | 2017 | 686 | 0.100 |
Why?
|
| Adult | 9 | 2022 | 31282 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2022 | 5196 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 1373 | 0.100 |
Why?
|
| Body Weight | 2 | 2019 | 987 | 0.100 |
Why?
|
| United States | 5 | 2020 | 12072 | 0.090 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 1410 | 0.090 |
Why?
|
| Transplantation, Homologous | 3 | 2022 | 670 | 0.090 |
Why?
|
| Pregnancy | 1 | 2025 | 7512 | 0.090 |
Why?
|
| Logistic Models | 3 | 2024 | 1797 | 0.090 |
Why?
|
| Liver | 4 | 2020 | 1796 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 3829 | 0.080 |
Why?
|
| Survival Rate | 3 | 2022 | 2114 | 0.080 |
Why?
|
| Pediatrics | 1 | 2019 | 1252 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2024 | 1378 | 0.070 |
Why?
|
| Prognosis | 3 | 2024 | 4886 | 0.060 |
Why?
|
| Liver Cirrhosis | 2 | 2023 | 903 | 0.060 |
Why?
|
| Middle Aged | 7 | 2020 | 28601 | 0.060 |
Why?
|
| Aged | 6 | 2020 | 21025 | 0.060 |
Why?
|
| Intention to Treat Analysis | 1 | 2024 | 59 | 0.050 |
Why?
|
| Young Adult | 4 | 2020 | 10103 | 0.050 |
Why?
|
| Hyponatremia | 1 | 2024 | 73 | 0.050 |
Why?
|
| Sodium | 1 | 2024 | 280 | 0.050 |
Why?
|
| Acute Disease | 2 | 2016 | 1153 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 2304 | 0.050 |
Why?
|
| Biopsy | 1 | 2026 | 1239 | 0.050 |
Why?
|
| Adenoviruses, Human | 1 | 2023 | 96 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 156 | 0.050 |
Why?
|
| Sex Factors | 1 | 2025 | 1356 | 0.040 |
Why?
|
| Protective Factors | 1 | 2021 | 91 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2023 | 262 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2026 | 807 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2023 | 579 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2019 | 3711 | 0.040 |
Why?
|
| Prevalence | 1 | 2026 | 2701 | 0.040 |
Why?
|
| Time Factors | 2 | 2019 | 6196 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 2019 | 123 | 0.030 |
Why?
|
| Operative Time | 1 | 2019 | 201 | 0.030 |
Why?
|
| Incidence | 1 | 2026 | 3360 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2021 | 282 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2019 | 761 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2016 | 5063 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 314 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 726 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 506 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 526 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1240 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1216 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1483 | 0.020 |
Why?
|
| Critical Illness | 1 | 2017 | 630 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2904 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2016 | 1717 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 6797 | 0.010 |
Why?
|